Login / Signup
Cross-specialty identification of the JAK1 inhibitor trial agent filgotinib as a potential therapy for alopecia areata.
Nicole Fagan
Glen A Doherty
Nekma Meah
Rodney Daniel Sinclair
Dmitri Wall
Published in:
The British journal of dermatology (2023)
Keyphrases
</>
study protocol
phase iii
clinical trial
phase ii
bioinformatics analysis
human health
randomized controlled trial
climate change